The antiviral medication remdesivir has been approved for immediate use in treating patients with coronavirus disease 2019 (COVID-19). Numerous studies have reported on the safety of this antiviral agent; however, the majority of these reports come from observation of extremely ill COVID-19 patients, leaving very little data available on moderately ill patients. The purpose of this research was to identify remdesivir-related adverse events (AEs) in patients with moderate-to-severe COVID-19 disease. Information on patients’ demographics, treatment with remdesivir, results of laboratory tests, and adverse events (AEs) were collected from May to July 2021 in a retrospective observational study and analyzed statistically. In addition to remdesivir, steroids, and low molecular weight heparin (LMW) heparin, 32 of the 160 COVID-19 patients were classified as moderately ill (males: 29, females: 03). A loading dose of 200 mg and a maintenance dose of 100 mg of remdesivir were typically given 4 times. There were a total of 41 adverse events (AEs) recorded, 17 of which were ADRs (an increase in alanine transaminase (ALT) [P<0.001]) and 23 AEs (a rise in RBS [one of the AEs] [P=0.007]). Patients with hypertension were more likely to experience the AEs. Around 4 patients experienced a major, serious AE, and it was an increased need for oxygen. In addition, elevated liver enzymes were found to be a side effect of remdesivir. The most common AE was elevated blood sugar, and the most serious AE was a need for additional oxygen.